Transcatheter Patent Foramen Ovale Closure in Patients With Transient Ischemic Attack.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 01 2023
Historique:
received: 22 09 2022
revised: 05 10 2022
accepted: 17 10 2022
pubmed: 3 12 2022
medline: 17 12 2022
entrez: 2 12 2022
Statut: ppublish

Résumé

Limited data exist on patients with a transient ischemic attack (TIA) who underwent patent foramen ovale (PFO) closure. The objectives of this study were to determine the clinical and procedural characteristics and long-term outcomes of patients with TIA who underwent transcatheter PFO closure. This was a multicenter study including 1,012 consecutive patients who underwent PFO closure after a cerebrovascular event. Patients were divided into 2 groups according to their index event leading to PFO closure: TIA (n = 183 [18%]), and stroke (n = 829 [82%]). The median follow-up was 3 (2 to 8) years (complete in 98% of patients). There were no significant differences between patients with TIA and stroke, except for a lower Risk of Paradoxical Embolism score in the TIA group (6.1 vs 6.9 in the stroke group, p <0.001). PFO closure was successful in all patients with a low rate of complications (<1%) in both groups. There were no differences in the incidence of neurologic events during long-term follow-up. There was 1 stroke event in the TIA group and 6 in the stroke group (0.08 vs 0.17 per 100 patients-years, p = 0.584). There were 2 TIA events in the TIA group and 10 in the stroke group (0.17 vs 0.28 per 100 patients-years, p = 0.557). In conclusion, our study showed that patients with TIA who underwent PFO closure have similar clinical characteristics as patients with stroke including a high Risk of Paradoxical Embolism score. Furthermore, these results suggest that PFO closure procedural results and long-term clinical outcomes are similar to their stroke counterparts, with a very low incidence of recurrent neurologic events. Further prospective randomized clinical trials are needed on this population.

Identifiants

pubmed: 36459738
pii: S0002-9149(22)01136-5
doi: 10.1016/j.amjcard.2022.10.044
pii:
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

148-153

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Julio I Farjat-Pasos (JI)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Paul Guedeney (P)

Cardiology Institute, Sorbonne University, Pitié-Salpetrière (AP-HP) University Hospital, Paris, France.

Christine Houde (C)

Quebec University Hospital Center, Laval University, Quebec City, Quebec, Canada.

Alberto Alperi (A)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Mathieu Robichaud (M)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Mélanie Côté (M)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Gilles Montalescot (G)

Cardiology Institute, Sorbonne University, Pitié-Salpetrière (AP-HP) University Hospital, Paris, France.

Josep Rodés-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Quebec University Hospital Center, Laval University, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH